COMMUNIQUÉS West-GlobeNewswire

CAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders

27/08/2024 - 14:00

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics, a clinical-stage biotechnology company developing a pipeline of RNA-based therapeutics designed to upregulate gene expression with the goal of [...]

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

27/08/2024 - 14:00

Exploration and evaluation of strategic alternatives continue WESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company [...]

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

27/08/2024 - 14:00

- Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting the ATEV was observed to have 12-month patency of 87.1% - - There were zero [...]

BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent

27/08/2024 - 14:00

VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development of 2- [...]

Rezolute to Participate in Upcoming Investor Conferences

27/08/2024 - 14:00

REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with [...]

Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery

27/08/2024 - 14:00

Study further validates highly reproducible drug response data. Enables AI platform to model and predict patient outcomes on historical samples Global biospecimen market valued at $4.4 billion in 2023, expected to grow [...]

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

27/08/2024 - 14:00

Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet age-related macular degeneration (wet AMD), including longest available interim follow-up data Overview of the [...]

Mahajan Therapeutics Unveils Brand Refresh

27/08/2024 - 14:00

LEWISVILLE, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mahajan Therapeutics, Ohio’s premier provider of mental health and addiction health services, is excited to announce a major brand refresh under the ownership of [...]

Larimar Therapeutics to Participate in Upcoming Investor Conferences

27/08/2024 - 14:00

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]

MIMEDX to Participate in Upcoming Investor Conferences

27/08/2024 - 14:00

MARIETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

27/08/2024 - 14:00

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway PITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: [...]

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

27/08/2024 - 14:00

CUPERTINO, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

InnovAge to Announce Fourth Quarter and Fiscal 2024 Financial Results and Host Conference Call Tuesday, September 10, 2024

27/08/2024 - 14:00

DENVER, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]

PetVivo Teams with Orthobiologic Innovations for Clincial Research and Product Commercialization

27/08/2024 - 14:00

Orthobiologic President & CEO, Sherman O. Canapp, Jr. and Director of Diagnositcs and Education, Debra Cannap, Join PetVivo Advisory Board MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Aug. 27, 2024 (GLOBE [...]

Entourage Health Reports Second Quarter 2024 Financial Results

27/08/2024 - 13:59

Total revenue of $12.2 million demonstrates the Company's solid momentum year over year and ongoing growth in the rapidly expanding bulk sales market. Entourage made a strong impact with new product launches across [...]

CERIS Announces Enhanced Offering to Fraud, Waste, and Abuse Solutions

27/08/2024 - 13:41

FORT WORTH, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Today, CERIS , a CorVel Company , has announced advancements to its current Fraud, Waste, and Abuse ( FWA ) solutions, including earlier detection capabilities and [...]

Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology

27/08/2024 - 13:30

USPTO issues Patent No. US 20230025693A1 (“ Patent ”) that covers Avicanna’s deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain TORONTO, Aug. 27, 2024 (GLOBE [...]

ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

27/08/2024 - 13:30

WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate [...]

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

27/08/2024 - 13:30

- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed [...]